PROLIFIC: Prognostic Lung Fibrosis Consortium
PROLIFIC: Prognostic Lung Fibrosis Consortium supports collaborating companies and foundations in developing blood-protein biomarker assays to advance drug development and targeted pulmonary fibrosis treatment.
Funder: Pulmonary Fibrosis Foundation
Due Dates: Membership inquiries welcomed; no deadline specified
Funding Amounts: Not specified
Summary: PROLIFIC brings organizations together to develop and validate blood-protein biomarker assays for pulmonary fibrosis drug development and targeted treatment.
Key Information: Participation begins with a consortium membership inquiry.
Description
The Prognostic Lung Fibrosis Consortium (PROLIFIC) was launched by the Pulmonary Fibrosis Foundation (PFF) and Bristol Myers Squibb to advance pulmonary fibrosis research and drug development. Pharmaceutical companies and foundations collaborate to create a company-agnostic assay that can guide targeted treatment strategies. The consortium studies early indicators of drug activity, with the long-term goal of identifying which patients would benefit most from particular treatments.
Members have agreed to focus on 12 promising blood-protein biomarkers across epithelial damage, fibrosis, inflammation, and thrombosis. Researchers screen samples from the PFF Registry to identify and validate these biomarkers. Once a multi-assay panel has been developed, members will test patient samples from the Registry’s biorepository to validate results, supporting more tailored treatment and simplifying collaborative research.
